Measurable residual disease (MRD) testing has become standard in AML and other cancers, to detect the presence of cancerous clones predictive of relapse and to guide early follow-up treatment decisions. Currently, flow cytometry and bulk next-generation sequencing are used to detect MRD, but these techniques have challenges with both sensitivity and specificity, limiting their prognostic value.
The new Tapestri scMRD technology using Mission Bio's Tapestri Platform is the industry's first approach integrating mutational profiles and immunophenotyptic signatures in the same individual cell, enabling scMRD detection with unparalleled resolution, sensitivity, and specificity. This approach enables deconstruction of the complex heterogeneity/somatic mosaicism driving disease transformation, and delineation between leukemic clones and clonal hematopoiesis, ultimately improving the identification of residual disease and potential therapeutic strategies.
Tapestri Platform resolves several challenges in MRD testing:
Unmask clonal architecture at diagnosis and during treatment and detect rare and subclonal variants driving the disease transformation
Characterize changes in clonal diversity over time, providing valuable information about tumor evolution and its correlation with relapse
Enable unambiguous distinction between leukemia driving clones and CH, reducing false positives
Integrate single-cell genotypic and immunophenotypic information for a comprehensive MRD assessment
Interested in learning more about our scMRD technology? Get a deeper dive into the scMRD Tapestri workflow here.
Mission Bio is now offering a Tapestri scMRD early access program to academic and translational research labs and pharmaceutical companies with acute myeloid leukemia (AML) samples. Sign up today to participate in the early access program.